ethyl glycinate hydrochloride | 1184979-76-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl glycinate hydrochloride
• 英文别名: 2-ethoxypropan-1-amine hydrochloride；2-Ethoxy-propylamine hydrochloride；2-ethoxypropan-1-amine;hydrochloride
• CAS: 1184979-76-7
• 化学式: C₅H₁₃NO*ClH
• 分子量: 139.625
• InChiKey: AZBRERYHQCIIAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.79
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4-chloro-1-(oxetan-3-yl)-1H-indole-3-carboxylic acid 、 ethyl glycinate hydrochloride 在 4-chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid (2-ethoxypropyl)amide 作用下， 以to afford the desired product 4-Chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid (2-ethoxy-propyl)-amide (8.00 mg; 0.02 mmol)的产率得到4-chloro-1-oxetan-3-yl-1H-indole-3-carboxylic acid (2-ethoxypropyl)amide
  参考文献：
  名称：

  NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES

  摘要：

  本发明涉及吲哚化合物及其药学上可接受的组合物，用作P2X7的拮抗剂，并用于治疗与P2X7相关的疾病。

  公开号：

  US20160168090A1

文献信息

• [EN] SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] BENZIMIDAZOLES SUBSTITUÉS, PRÉPARATION ET UTILISATION DE CEUX-CI EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：NEOMED INST

  公开号：WO2017024412A1

  公开（公告）日：2017-02-16

  This application relates to substituted benzimidazoles of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application also relates to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasm, including tumors and/or cancers.

  本申请涉及到式(I)的取代苯并咪唑化合物，包括它们的组合物以及它们在治疗疾病和病况中的用途，其中需要抑制溴结构域。例如，本申请涉及到取代苯并咪唑化合物及其作为溴结构域抑制剂的用途。本申请还涉及到治疗或预防增生性疾病、自身免疫性疾病、炎症性疾病、皮肤疾病以及新生物，包括肿瘤和/或癌症。
• One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives
  作者：Mehdi Ghandi、Fatemeh Sherafat、Masoud Sadeghzadeh、Behrouz Alirezapour

  DOI：10.1016/j.bmcl.2016.04.010

  日期：2016.6

  6-diketopiperazine derivatives containing benzylpiperidine and cycloalkane moieties were synthesized by a one-pot two-step sequential Ugi/intramolecular N-amidation process in moderate to good yields. The in vitro ligand-binding profile studies performed on the sigma-1 and sigma-2 receptors revealed that the σ1 affinities and subtype selectivities of three spirocyclic piperidine derivatives are generally

  通过一锅两步连续的Ugi /分子内N酰胺化工艺合成了含有苄基哌啶和环烷烃部分的新螺环2,6-二酮哌嗪衍生物，产率中等至良好。体外配体结合研究轮廓在σ-1和σ-2受体进行显示，该σ 1倍的亲和力和三个螺环哌啶衍生物的亚型选择性是通常与那些spirocycloalkane类似物。相比于低σ 1个为环烷基取代的螺环-2,6-二酮哌嗪类与获得的亲和力Ñ  = 2，那些具有Ñ  = 1证明具有最佳拟合与σ 2亚型表现出更高的亲和力。此外，最好的结合亲和力和亚型选择性鉴定为化合物3C与ķ我σ 1  = 5.9±0.5nM的和ķ我σ 2  = 563±21纳米以及95倍σ 1 /σ 2分别选择性比。
• [EN] 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2<br/>[FR] DÉRIVÉS DE 1,1-DIOXYDE DE 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE EN TANT QU'INHIBITEURS DE MRGX2
  申请人：SOLENT THERAPEUTICS LLC

  公开号：WO2020223255A1

  公开（公告）日：2020-11-05

  Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R1, R2, R3, R4 and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

  本公开涉及Formula (1)的化合物及其互变异构体，以及这些化合物或互变异构体的药用可接受盐，其中L、R1、R2、R3、R4和R5在说明书中有定义。本公开还涉及制备Formula (1)化合物的材料和方法，含有这些化合物的药物组合物，以及它们用于治疗与MRGX2相关的疾病、疾患或症状的用途。
• Indole derivatives and their use in neurodegenerative diseases
  申请人：Merck Patent GmbH

  公开号：US10323000B2

  公开（公告）日：2019-06-18

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及作为 P2X7 拮抗剂和用于治疗 P2X7 相关疾病的吲哚化合物及其药学上可接受的组合物。
• Substituted benzimidazoles, their preparation and their use as pharmaceuticals
  申请人：NEOMED Institute

  公开号：US10703740B2

  公开（公告）日：2020-07-07

  This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

  本申请涉及取代的苯并咪唑、包含它们的组合物以及它们在治疗需要抑制溴链的疾病和病症中的用途。例如，本申请涉及取代的苯并咪唑类化合物及其作为溴链抑制剂的用途。本申请还涉及增殖性疾病、自身免疫性疾病、炎症性疾病、皮肤疾病和肿瘤（包括肿瘤和/或癌症）的治疗或预防。